vs
汇丰控股有限公司（HSBC）与强生（JNJ）财务数据对比。点击上方公司名可切换其他公司
汇丰控股有限公司的季度营收约是强生的1.2倍（$28.6B vs $24.6B），汇丰控股有限公司净利率更高（25.7% vs 20.8%，领先4.9%），汇丰控股有限公司自由现金流更多（$64.0B vs $5.5B）
汇丰控股有限公司是总部位于英国伦敦的全能银行及金融服务集团，历史与业务均与东亚市场渊源深厚，业务布局覆盖全球。截至2024年9月，集团总资产达3.098万亿美元，为欧洲规模最大的银行，全球总资产排名第7位，同时是全球第三大非国有银行。
强生是美国跨国制药、生物技术及医疗技术企业，总部位于新泽西州新不伦瑞克，在纽约证券交易所上市，普通股为道琼斯工业平均指数成分股，2025年位列财富美国500强第48位、福布斯全球企业2000强第42位。
HSBC vs JNJ — 直观对比
营收规模更大
HSBC
是对方的1.2倍
$24.6B
净利率更高
HSBC
高出4.9%
20.8%
自由现金流更多
HSBC
多$58.5B
$5.5B
损益表 — Q4 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $28.6B | $24.6B |
| 净利润 | $7.3B | $5.1B |
| 毛利率 | — | 67.6% |
| 营业利润率 | 33.1% | 20.2% |
| 净利率 | 25.7% | 20.8% |
| 营收同比 | — | 9.1% |
| 净利润同比 | — | 49.1% |
| 每股收益（稀释后） | $0.36 | $2.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HSBCJNJ
| Q4 25 | — | $24.6B | ||
| Q3 25 | — | $24.0B | ||
| Q2 25 | — | $23.7B | ||
| Q1 25 | $28.6B | $21.9B | ||
| Q4 24 | — | $22.5B | ||
| Q3 24 | — | $22.5B | ||
| Q2 24 | — | $22.4B | ||
| Q1 24 | — | $21.4B |
净利润HSBCJNJ
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $5.2B | ||
| Q2 25 | — | $5.5B | ||
| Q1 25 | $7.3B | $11.0B | ||
| Q4 24 | — | $3.4B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $4.7B | ||
| Q1 24 | — | $3.3B |
毛利率HSBCJNJ
| Q4 25 | — | 67.6% | ||
| Q3 25 | — | 69.6% | ||
| Q2 25 | — | 67.9% | ||
| Q1 25 | — | 66.4% | ||
| Q4 24 | — | 68.3% | ||
| Q3 24 | — | 69.0% | ||
| Q2 24 | — | 69.4% | ||
| Q1 24 | — | 69.6% |
营业利润率HSBCJNJ
| Q4 25 | — | 20.2% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | — | 27.3% | ||
| Q1 25 | 33.1% | 62.3% | ||
| Q4 24 | — | 17.3% | ||
| Q3 24 | — | 14.9% | ||
| Q2 24 | — | 25.6% | ||
| Q1 24 | — | 17.4% |
净利率HSBCJNJ
| Q4 25 | — | 20.8% | ||
| Q3 25 | — | 21.5% | ||
| Q2 25 | — | 23.3% | ||
| Q1 25 | 25.7% | 50.2% | ||
| Q4 24 | — | 15.2% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | — | 20.9% | ||
| Q1 24 | — | 15.2% |
每股收益（稀释后）HSBCJNJ
| Q4 25 | — | $2.08 | ||
| Q3 25 | — | $2.12 | ||
| Q2 25 | — | $2.29 | ||
| Q1 25 | $0.36 | $4.54 | ||
| Q4 24 | — | $1.41 | ||
| Q3 24 | — | $1.11 | ||
| Q2 24 | — | $1.93 | ||
| Q1 24 | — | $1.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $434.9B | $20.1B |
| 总债务越低越好 | — | $41.4B |
| 股东权益账面价值 | $192.3B | $81.5B |
| 总资产 | $3017.0B | $199.2B |
| 负债/权益比越低杠杆越低 | — | 0.51× |
8季度趋势，按日历期对齐
现金及短期投资HSBCJNJ
| Q4 25 | — | $20.1B | ||
| Q3 25 | — | $18.6B | ||
| Q2 25 | — | $18.9B | ||
| Q1 25 | $434.9B | $38.8B | ||
| Q4 24 | — | $24.5B | ||
| Q3 24 | — | $20.3B | ||
| Q2 24 | — | $25.5B | ||
| Q1 24 | — | $26.2B |
总债务HSBCJNJ
| Q4 25 | — | $41.4B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $32.4B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HSBCJNJ
| Q4 25 | — | $81.5B | ||
| Q3 25 | — | $79.3B | ||
| Q2 25 | — | $78.5B | ||
| Q1 25 | $192.3B | $78.1B | ||
| Q4 24 | — | $71.5B | ||
| Q3 24 | — | $70.2B | ||
| Q2 24 | — | $71.5B | ||
| Q1 24 | — | $70.0B |
总资产HSBCJNJ
| Q4 25 | — | $199.2B | ||
| Q3 25 | — | $192.8B | ||
| Q2 25 | — | $193.4B | ||
| Q1 25 | $3017.0B | $193.7B | ||
| Q4 24 | — | $180.1B | ||
| Q3 24 | — | $178.3B | ||
| Q2 24 | — | $181.1B | ||
| Q1 24 | — | $172.0B |
负债/权益比HSBCJNJ
| Q4 25 | — | 0.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $65.3B | $7.3B |
| 自由现金流经营现金流 - 资本支出 | $64.0B | $5.5B |
| 自由现金流率自由现金流/营收 | 223.9% | 22.3% |
| 资本支出强度资本支出/营收 | 4.7% | 7.5% |
| 现金转化率经营现金流/净利润 | 8.90× | 1.43× |
| 过去12个月自由现金流最近4个季度 | — | $19.7B |
8季度趋势，按日历期对齐
经营现金流HSBCJNJ
| Q4 25 | — | $7.3B | ||
| Q3 25 | — | $9.2B | ||
| Q2 25 | — | $3.9B | ||
| Q1 25 | $65.3B | $4.2B | ||
| Q4 24 | — | $7.0B | ||
| Q3 24 | — | $8.0B | ||
| Q2 24 | — | $5.6B | ||
| Q1 24 | — | $3.7B |
自由现金流HSBCJNJ
| Q4 25 | — | $5.5B | ||
| Q3 25 | — | $8.0B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | $64.0B | $3.4B | ||
| Q4 24 | — | $5.4B | ||
| Q3 24 | — | $7.0B | ||
| Q2 24 | — | $4.7B | ||
| Q1 24 | — | $2.9B |
自由现金流率HSBCJNJ
| Q4 25 | — | 22.3% | ||
| Q3 25 | — | 33.4% | ||
| Q2 25 | — | 11.9% | ||
| Q1 25 | 223.9% | 15.4% | ||
| Q4 24 | — | 23.8% | ||
| Q3 24 | — | 31.0% | ||
| Q2 24 | — | 20.7% | ||
| Q1 24 | — | 13.3% |
资本支出强度HSBCJNJ
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 4.4% | ||
| Q1 25 | 4.7% | 3.6% | ||
| Q4 24 | — | 7.2% | ||
| Q3 24 | — | 4.6% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | 3.8% |
现金转化率HSBCJNJ
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.78× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | 8.90× | 0.38× | ||
| Q4 24 | — | 2.04× | ||
| Q3 24 | — | 2.97× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HSBC
暂无分部数据
JNJ
| Other | $14.2B | 58% |
| Immunology | $2.5B | 10% |
| Orthopaedics | $1.5B | 6% |
| Neuroscience | $1.4B | 6% |
| Cardiovascular | $1.4B | 6% |
| Surgery | $1.1B | 4% |
| Pulmonary Hypertension | $865.0M | 4% |
| Cardiovascular Metabolism Other | $794.0M | 3% |
| Vision | $531.0M | 2% |
| Infectious Diseases | $303.0M | 1% |
